Adipose Tissue Secretome Biomarkers in Metabolic Health

Abstract

The adipose tissue secretome, comprising a diverse array of bioactive molecules such as adipokines, cytokines, and extracellular vesicles, plays a central role in modulating systemic metabolic health. Mounting research elucidates the complex interplay between these secreted factors and the pathogenesis of metabolic disorders, including obesity, type 2 diabetes mellitus, and cardiovascular disease. This review aims to synthesize current evidence regarding clinically relevant adipose tissue secretome biomarkers, highlighting their mechanistic roles, diagnostic potential, and implications for personalized management in metabolic health.

Introduction

Adipose tissue, once regarded merely as an energy storage depot, is now recognized as a dynamic endocrine organ with profound systemic effects mediated through its secretome. The secretome encompasses a wide array of molecules adipokines, chemokines, cytokines, and lipid mediators that regulate metabolic processes, inflammation, and insulin sensitivity. Understanding the clinical relevance of these secreted biomarkers is crucial for early diagnosis, risk stratification, and targeted therapies in metabolic disease. This article provides an in-depth overview of the adipose tissue secretome, emphasizing its biomarkers in the context of metabolic health and disease.

Epidemiology / Disease Burden

The global burden of metabolic diseases, particularly obesity, type 2 diabetes mellitus (T2DM), and metabolic syndrome, has escalated dramatically in recent decades. According to the World Health Organization, more than 650 million adults worldwide are obese, and over 460 million live with diabetes. These conditions are closely linked to adipose tissue dysfunction and altered secretory profiles. The prevalence of metabolic syndrome, characterized by central adiposity, dyslipidemia, hypertension, and hyperglycemia, underscores the clinical importance of identifying robust biomarkers for early intervention. The rising incidence of these disorders highlights the urgent need for improved diagnostic and prognostic tools, many of which may be derived from the adipose tissue secretome.

Pathophysiology

Adipose tissue secretes a complex mixture of bioactive molecules that exert paracrine, autocrine, and endocrine effects. Key adipokines such as adiponectin, leptin, resistin, and visfatin modulate insulin sensitivity, energy expenditure, and inflammatory pathways. In obesity, there is a shift toward a proinflammatory secretome profile, characterized by increased production of tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and monocyte chemoattractant protein-1 (MCP-1), along with decreased anti-inflammatory adipokines like adiponectin. This dysregulated secretome contributes to chronic low-grade inflammation, insulin resistance, endothelial dysfunction, and atherogenesis. Recent studies also implicate extracellular vesicles and non-coding RNAs from adipose tissue as novel mediators in metabolic disease pathogenesis.

Risk Factors

Several factors influence the composition of the adipose tissue secretome and its impact on metabolic health. Major risk factors include genetic predisposition, sedentary lifestyle, excess caloric intake, aging, and chronic stress. Visceral adiposity, more than subcutaneous fat, is particularly associated with a deleterious secretome profile and heightened cardiometabolic risk. Other modifying factors include sex hormones, ethnicity, and the presence of comorbidities such as non-alcoholic fatty liver disease and polycystic ovary syndrome. Understanding these risk determinants aids in the identification of high-risk individuals who may benefit from targeted secretome biomarker assessment.

Clinical Features

Patients with metabolic dysregulation due to adipose tissue secretome imbalance typically present with features of metabolic syndrome, including central obesity, impaired glucose tolerance, dyslipidemia (elevated triglycerides, low HDL cholesterol), hypertension, and hepatic steatosis. Subclinical inflammation, as reflected by elevated circulating C-reactive protein (CRP) and proinflammatory cytokines, is common. In advanced stages, patients may develop overt diabetes, cardiovascular complications, or non-alcoholic steatohepatitis. The clinical phenotype often correlates with specific secretome biomarker profiles, supporting their utility in risk stratification and disease monitoring.

Diagnosis

The diagnostic evaluation of metabolic health increasingly incorporates assessment of adipose tissue-derived biomarkers. Traditional risk factors BMI, waist circumference, fasting glucose, and lipid profile are now complemented by measurement of adipokines such as adiponectin, leptin, and resistin. Low adiponectin and high leptin levels are associated with insulin resistance and cardiovascular risk. Proinflammatory cytokines (e.g., TNF-α, IL-6) and novel markers such as fatty acid-binding protein 4 (FABP4) and retinol-binding protein 4 (RBP4) have demonstrated utility in early detection of metabolic dysfunction. Advanced omics approaches, including proteomics and metabolomics, are enabling the discovery of new secretome biomarkers with diagnostic and prognostic relevance.

Treatment & Management

The management of metabolic disorders involves a multifaceted approach targeting lifestyle modification, pharmacotherapy, and in select cases, bariatric surgery. Interventions aimed at reducing adiposity can favorably alter the adipose tissue secretome, restoring a healthier balance of adipokines and inflammatory mediators. Pharmacologic agents such as thiazolidinediones, GLP-1 receptor agonists, and SGLT2 inhibitors may also modulate the secretome, improving insulin sensitivity and reducing inflammation. Personalized medicine strategies incorporating secretome biomarker profiling may facilitate individualized risk assessment and therapy selection, optimizing clinical outcomes.

Recent Advances / Emerging Therapies

Recent advances in the field include the identification of novel adipose tissue-derived exosomal microRNAs and long non-coding RNAs as sensitive biomarkers of metabolic dysfunction. Emerging therapies targeting specific secretome components such as monoclonal antibodies against proinflammatory cytokines or agents enhancing adiponectin signaling show promise in preclinical and early clinical studies. High-throughput proteomic and lipidomic profiling of the adipose secretome is uncovering new targets for intervention and providing deeper mechanistic insights into disease progression. These innovations are paving the way for more precise, mechanism-based management of metabolic disorders.

Guideline Recommendations

Contemporary clinical guidelines emphasize the importance of comprehensive risk assessment in metabolic health, incorporating both traditional risk factors and emerging biomarkers. The American Diabetes Association and European Society of Cardiology recognize the utility of adipokine measurement particularly adiponectin and leptin in selected high-risk populations. However, routine clinical use of advanced secretome biomarkers awaits further validation in large-scale prospective studies. Current guidelines advocate for ongoing research to refine the clinical integration of these novel biomarkers into routine practice, with the goal of enhancing early detection, risk stratification, and personalized therapy.

Conclusion

The adipose tissue secretome represents a rich source of clinically informative biomarkers with significant potential to enhance the management of metabolic diseases. As our understanding of the molecular underpinnings and clinical implications of these secreted factors evolves, integration of secretome biomarker profiling into routine care may revolutionize the prevention, early diagnosis, and individualized treatment of metabolic disorders. Continued translational research and validation in diverse populations are essential to realize the full promise of adipose tissue secretome biomarkers in metabolic health.